Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence

Patients using both glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors had a significantly lower risk of major adverse kidney events compared to those using sodium-glucose cotransporter 2 inhibitors alone.

• The combination therapy resulted in a hazard ratio of 0.73 for major adverse kidney events.
• A lower risk of acute kidney injury was observed with a hazard ratio of 0.82 for the combination therapy.
• End-stage kidney disease risk decreased significantly, with a hazard ratio of 0.61 for patients on both treatments.
• All-cause mortality was also reduced, indicated by a hazard ratio of 0.54 in the dual therapy group.
• Subgroup analyses demonstrated consistent benefits across various patient demographics.

AI simplified